AprilBio에이프릴바이오
397030 · KOSDAQ · ₩397030 · 에이프릴바이오
₩12,340▼ ₩60 (0.48%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩2.2B | ₩28B | ₩0 | ₩200M |
| Operating income | −₩7.3B | ₩17B | −₩13B | −₩11B |
| Net income | −₩9.7B | ₩20B | −₩14B | −₩9B |
| Net income to shareholders | −₩9.7B | ₩20B | −₩14B | −₩9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩97B | ₩100B | ₩80B | ₩71B |
| Current assets | ₩95B | ₩97B | ₩67B | ₩69B |
| Cash and equivalents | ₩7.1B | ₩3.3B | ₩6.6B | ₩7.3B |
| Total liabilities | ₩804M | ₩8.6B | ₩22B | ₩1.9B |
| Current liabilities | ₩542M | ₩8.5B | ₩22B | ₩1.8B |
| Borrowings | ₩0 | ₩2.7B | ₩5.5B | ₩1.4B |
| Total equity | ₩96B | ₩91B | ₩58B | ₩69B |
| Shareholders' equity | ₩96B | ₩91B | ₩58B | ₩69B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | −₩3.3B | ₩22B | −₩10B | −₩6.7B |
| Capital spending | ₩42M | ₩297M | ₩53M | — |
| Free cash flow | −₩3.4B | ₩22B | −₩10B | −₩6.7B |
| Dividends paid | ₩0 | ₩0 | ₩0 | — |
Consolidated where available. Amounts in won.
Also known as: AprilBio / 에이프릴바이오 / 397030 / KRX:397030
Source: KRX statistical information